Research programme: mRNA-lipid nanoparticle immunotherapies - Epitopea/Genevant Sciences
Alternative Names: mRNA-LNP immunotherapies - Epitopea/Genevant SciencesLatest Information Update: 31 Jan 2025
Price :
$50 *
At a glance
- Originator Epitopea; Genevant Sciences
- Class Antineoplastics; Immunotherapies; RNA
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Cancer